Large language models (LLMs) are used increasingly in medicine, but their decision-making in cardiovascular risk attribution remains underexplored. This pilot study examined how an LLM apportioned relative cardiovascular risk across different demographic and clinical domains. A structured prompt set across six domains was developed, across general cardiovascular risk, body mass index (BMI), diabetes, depression, smoking, […]
Moderna lands CEPI as new backer for its pandemic flu program
Moderna has snagged a new partner to help pay for a Phase 3 study of its H5 pandemic influenza vaccine, more than six months after the US axed funding for the project. The Coalition for …
GSK turns to Camp4 for neuro and kidney medicines
GSK will enlist regulatory RNA biotech Camp4 Therapeutics to help find and create new neurodegenerative and kidney disease medicines. The deal is worth $17.5 million upfront, and as much as $440 million in development and …
Takeda plans filings for Sotyktu rival on new psoriasis data
Takeda intends to file for approval of its oral psoriasis therapy zasocitinib next year, with Bristol Myers Squibb’s Sotyktu in its sights.
Lilly’s orforglipron is the first oral obesity therapy to show its worth in the maintenance setting
Eli Lilly’s experimental obesity pill allowed patients who had lost weight on injected GLP-1-based drugs to keep most of the weight off for another year, according to data from a Phase 3 trial released Thursday …
Medtronic encourages people with Type 1 diabetes to ‘Own It’ in new MiniMed campaign
As Medtronic begins rolling out a recently FDA-cleared diabetes management system combining its MiniMed 780G insulin pump and Abbott’s Instinct glucose sensor, the medtech giant has launched a new campaign to promote the duo.
Steve Paul’s post-Karuna act draws $165M to schizophrenia biotech Syremis
Steve Paul is back with a fresh take on schizophrenia drugs, co-founding a new biotech called Syremis Therapeutics that’s already landed $165 million in a Series A, Endpoints News has learned. The serial founder and …
MSD claims two national priority vouchers; report
The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.
As year-end nears, pharma groups boost their pipelines
Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.
As year-end nears, pharma groups plump up their pipelines
Bristol Myers Squibb, Sanofi, Pfizer, Roche, and Yarrow Bioscience all added to their pipelines this week in an end-of-year licensing deal flurry.